


What is claimed is:

1. A compound of Formula (I):



wherein Z is $-\text{CHR}^9-$, $-\text{C}(\text{O})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{SO}_2-$, $-\text{N}(\text{R}^9)-$, $-\text{C}(\text{O})\text{N}(\text{R}^9)-$, or $-\text{N}(\text{R}^9)\text{C}(\text{O})-$;

1 is 1 or 2;

m is 0, 1 or 2;

n is 1 or 2;

R¹ and R² are each independently hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, or (C₃₋₆cycloalkyl)C₁₋₆alkyl; provided that R¹ and R² are not both hydrogen;

R³ is hydrogen or C₁₋₆alkyl;

R⁴, R⁵, and R⁹ are independently hydrogen, C₁₋₆alkyl or arylC₁₋₆alkylene;

R⁶, R⁷, and R⁸ are independently hydrogen, fluoro, chloro, bromo, CF₃, -OCF₃, -N(R¹⁰)₂, C₁₋₆alkyl, C₁₋₆alkoxy, heteroaryl or aryl;

each R¹⁰ is independently hydrogen, or -C₁₋₆alkyl;

wherein any C₁₋₆alkyl, C₁₋₆alkylene, or C₁₋₆alkoxy of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ is optionally partially unsaturated;

wherein any heteroaryl or aryl is optionally substituted with one or two substituents independently

selected from halo, $-\text{CF}_3$, $-\text{OCF}_3$, C_{1-6} alkoxy, $-\text{N}(\text{R}^{10})_2$, and C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 is hydrogen.
3. The compound of claim 1, wherein R^1 is C_{1-6} alkyl, C_{3-6} cycloalkyl, or $(\text{C}_{3-6}\text{cycloalkyl})\text{C}_{1-6}$ alkyl.
4. The compound of claim 1, wherein R^1 is C_{2-6} alkyl, C_{3-6} cycloalkyl, or $(\text{C}_{3-6}\text{cycloalkyl})\text{C}_{1-6}$ alkyl.
5. The compound of claim 1, wherein R^1 is C_{3-6} alkyl, C_{3-6} cycloalkyl, or $(\text{C}_{3-6}\text{cycloalkyl})\text{C}_{1-6}$ alkyl.
6. The compound of claim 1, wherein R^1 is methyl, ethyl, propyl, isopropyl, or cyclopropylmethyl.
7. The compound of claim 1, wherein R^1 is ethyl, propyl, isopropyl, or cyclopropylmethyl.
8. The compound of claim 1, wherein R^1 is propyl, isopropyl, or cyclopropylmethyl.
9. The compound of claim 1, wherein R^2 is hydrogen.
10. The compound of claim 1, wherein R^2 is C_{1-6} alkyl, C_{3-6} cycloalkyl, or $(\text{C}_{3-6}\text{cycloalkyl})\text{C}_{1-6}$ alkyl.

11. The compound of claim 1, wherein R^2 is C_{2-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl.

12. The compound of claim 1, wherein R^2 is C_{3-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl.

13. The compound of claim 1, wherein R^2 is methyl, ethyl, propyl, isopropyl, or cyclopropylmethyl.

14. The compound of claim 1, wherein R^2 is ethyl, propyl, isopropyl, or cyclopropylmethyl.

15. The compound of claim 1, wherein R^2 is propyl, isopropyl, or cyclopropylmethyl.

16. The compound of claim 10, wherein R^1 is hydrogen.

17. The compound of claim 1, wherein R^1 is C_{2-3} alkyl and R^2 is hydrogen, or C_{2-6} alkyl.

18. The compound of claim 1, wherein R^1 is hydrogen, or C_{2-3} alkyl; and R^2 is C_{2-6} alkyl.

19. The compound of claim 1, wherein R^1 is C_{2-3} alkyl and R^2 is C_{2-6} alkyl.

20. The compound of claim 1, wherein R^1 is ethyl or propyl and R^2 is ethyl, propyl or butyl.

21. The compound of claim 1, wherein R^3 is hydrogen.
22. The compound of claim 1, wherein R^3 is C_{1-6} alkyl.
23. The compound of claim 23, wherein; and R^3 is methyl, ethyl, propyl, or butyl.
24. The compound of claim 23, wherein; and R^3 is methyl or ethyl.
25. The compound of claim 1, wherein R^4 and R^5 are independently hydrogen, methyl, ethyl, propyl, butyl, 2-phenylethyl, or benzyl.
26. The compound of claim 25, wherein R^4 and R^5 are independently hydrogen, methyl, ethyl, propyl, or benzyl.
27. The compound of claim 25, wherein R^4 and R^5 are independently methyl, ethyl, or benzyl.
28. The compound of claim 1, wherein R^6 , R^7 , or R^8 is phenyl optionally substituted with one or two substituents independently selected from halo, $-CF_3$, $-OCF_3$, C_{1-6} alkoxy, $-N(R^{10})_2$, and C_{1-6} alkyl.
29. The compound of claim 28, wherein R^6 , R^7 , or R^8 is phenyl optionally substituted with one or two substituents independently selected from fluoro, chloro, bromo, $-CF_3$, $-OCF_3$, C_{1-6} alkoxy and $-N(R^{10})_2$.

30. The compound of claim 28, wherein R⁶, R⁷, or R⁸ is phenyl optionally substituted with one or two substituents independently selected from fluoro, chloro, and bromo.

31. The compound of claim 28, wherein R⁶ is 2,4-dichlorophenyl or 2,6-difluorophenyl.

32. The compound of claim 28, wherein R⁷ is 2,4-dichlorophenyl or 2,6-difluorophenyl.

33. The compound of claim 28, wherein R⁸ is 2,4-dichlorophenyl or 2,6-difluorophenyl.

34. The compound of claim 1 which is 6b-methyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole; or a pharmaceutically acceptable salt thereof.

35. The compound of claim 1 which is
5-(2,4-dichlorophenyl)-10a-methyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole;

5-(2,6-difluorophenyl)-10a-methyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole;

5-(2,4-dichlorophenyl)-10a-ethyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole;

5-(2,6-difluorophenyl)-10a-ethyl-
1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-
hi]pyrido[4,3-b]indole;

5-(2,4-dichlorophenyl)-10a-methyl-
1,2,6b,7,8,9,10,10a-octahydropyrido[4,3-
b][1,4]thiazino[2,3,4-hi]indole;

5-(2,6-difluorophenyl)-10a-methyl-
1,2,6b,7,8,9,10,10a- octahydropyrido[4,3-
b][1,4]thiazino[2,3,4-hi]indole;

5-(2,4-dichlorophenyl)-10a-ethyl-
1,2,6b,7,8,9,10,10a- octahydropyrido[4,3-
b][1,4]thiazino[2,3,4-hi]indole; or

5-(2,6-difluorophenyl)-10a-ethyl-
1,2,6b,7,8,9,10,10a- octahydropyrido[4,3-
b][1,4]thiazino[2,3,4-hi]indole;

or a pharmaceutically acceptable salt thereof.

36. A pharmaceutical composition comprising a
compound of claim 1 and a pharmaceutically acceptable
excipient.

37. A compound of claim 1 for use in medical
diagnosis or therapy.

38. The compound of claim 37, wherein the therapy
is the treatment of a disease or disorder of the central
nervous system.

39. The compound of claim 37, wherein the therapy is the treatment of anxiety, obesity, depression, or a stress related disease.

40. The use of a compound of claim 1 to prepare a medicament for treating or preventing a disease or disorder of the central nervous system.


41. The use of claim 40, wherein the disease or disorder of the central nervous system is anxiety, obesity, depression, or a stress related disease.

42. A method for treating a disease or condition in a mammal in need thereof wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising administering a therapeutically effective amount of a compound of claim 1 to the mammal.

43. The method of claim 42, wherein the disease is anxiety, obesity, depression, or a stress related disease.

44. A method for treating or preventing a disease or disorder of the central nervous system in a mammal in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 to the mammal.

45. A compound of Formula (II):



(II)

wherein Z is $-\text{CHR}^9-$, $-\text{C}(\text{O})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{SO}_2-$, $-\text{N}(\text{R}^9)-$, $-\text{C}(\text{O})\text{N}(\text{R}^9)-$, or $-\text{N}(\text{R}^9)\text{C}(\text{O})-$;

l is 1 or 2;

m is 0, 1 or 2;

n is 1 or 2;

R^1 and R^2 are each independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or $(\text{C}_{3-6}$ cycloalkyl) C_{1-6} alkyl; provided that R^1 and R^2 are not both hydrogen;

R^3 is $-\text{C}(\text{O})$ -aryl, $-\text{C}(\text{O})$ -heteroaryl, $-\text{C}(\text{O})$ - C_{1-6} alkyl, $-\text{C}(\text{O})$ - C_{1-6} haloalkyl, $-\text{C}(\text{O})\text{O}$ - C_{1-6} alkyl, or $-\text{C}(\text{O})\text{O}$ - C_{1-6} haloalkyl, where aryl or heteroaryl is optionally substituted with one or two halo, $-\text{CF}_3$, $-\text{OCF}_3$, C_{1-6} alkoxy, $-\text{N}(\text{R}^{10})_2$, or $-\text{C}_{1-6}$ alkyl;

R^4 , R^5 , and R^9 are independently hydrogen, C_{1-6} alkyl or aryl C_{1-6} alkylene;

R^6 , R^7 , and R^8 are independently hydrogen, fluoro, chloro, bromo, CF_3 , $-\text{OCF}_3$, $-\text{N}(\text{R}^{10})_2$, C_{1-6} alkyl, C_{1-6} alkoxy, heteroaryl or aryl;

each R^{10} is independently hydrogen, or $-\text{C}_{1-6}$ alkyl;

wherein any C_{1-6} alkyl, C_{1-6} alkylene, or C_{1-6} alkoxy of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , and R^{10} is optionally partially unsaturated;

wherein any heteroaryl or aryl is optionally substituted with one or two substituents independently selected from halo, -CF₃, -OCF₃, C₁₋₆alkoxy, -N(R¹⁰)₂, and C₁₋₆alkyl.

46. The compound of claim 45 which is
tert-Butyl 6b-methyl-1,2,6b,9,10,10a-hexahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole-8(7H)-carboxylate;

tert-butyl-5-(2,4-dichlorophenyl)-10a-methyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole-8(7H)-carboxylate;

tert-butyl-5-(2,6-difluorophenyl)-10a-methyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole-8(H)-carboxylate;

tert-butyl-5-(2,4-dichlorophenyl)-10a-ethyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole-8(7H)-carboxylate;

tert-butyl-5-(2,6-difluorophenyl)-10a-ethyl-1,2,6b,7,8,9,10,10a-octahydro[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole-8(7H)-carboxylate;

tert-butyl-5-(2,4-dichlorophenyl)-10a-methyl-1,2,6b,7,8,9,10,10a-octahydropyrido[4,3-b][1,4]thiazino[2,3,4-hi]indole-8(7H)-carboxylate;

tert-butyl-5-(2,6-difluorophenyl)-10a-methyl-1,2,6b,7,8,9,10,10a-octahydropyrido[4,3-b][1,4]thiazino[2,3,4-hi]indole-8(7H)-carboxylate;

tert-butyl-5-(2,4-dichlorophenyl)-10a-ethyl-1,2,6b,7,8,9,10,10a-octahydropyrido[4,3-b][1,4]thiazino[2,3,4-hi]indole-8(7H)-carboxylate; or

tert-butyl-5-(2,6-difluorophenyl)-10a-ethyl-
1,2,6b,7,8,9,10,10a- octahydropyrido[4,3-
b][1,4]thiazino[2,3,4-hi]indole.

47. The compound of Claim 46, which is tert-butyl
6b-methyl-1,2,6b,9,10,10a-hexahydro[1,4]oxazino[2,3,4-
hi]pyrido[4,3-b]indole-8(7H)-carboxylate.